Cutaneous mucormycosis

The Rising Threat of Mucormycosis: Oman’s Experience Before and During the COVID-19 Pandemic

mycolabadmin

Mucormycosis is a serious fungal infection that became much more common in Oman during the COVID-19 pandemic. Most patients had diabetes and nearly half had COVID-19, with very high death rates. The infection primarily affects the sinuses and brain, and requires aggressive treatment with surgery and antifungal medications. This study shows doctors need better tools to detect and treat this dangerous infection, especially during health crises.

Continuous debridement combined with short-term posaconazole therapy for cutaneous mucormycosis caused by Rhizopus oryzae infection secondary to acute myeloid leukemia: a case report

mycolabadmin

An 80-year-old patient with acute myeloid leukemia developed a serious fungal skin infection caused by Rhizopus oryzae on his lower leg. Doctors treated the infection by repeatedly cleaning out the infected tissue and giving him an antifungal medication called posaconazole for just one week. Despite the short treatment duration due to cost concerns, the patient’s wound gradually healed over four months through continued surgical care, showing that sometimes focused surgical treatment can be as effective as long-term medication.

Brazilian task force for the management of mucormycosis

mycolabadmin

Mucormycosis is a serious fungal infection that has become more common in Brazil, especially during COVID-19. This medical emergency requires rapid diagnosis through imaging and tissue sampling, combined with aggressive treatment including antifungal medications and surgery to remove infected tissue. The Brazilian government has made these powerful antifungal drugs more available to improve patient survival and reduce the severe complications of this dangerous infection.

Monoclonal Antibodies Can Aid in the Culture-Based Detection and Differentiation of Mucorales Fungi—The Flesh-Eating Pathogens Apophysomyces and Saksenaea as an Exemplar

mycolabadmin

This research developed a special antibody test to quickly identify deadly flesh-eating fungi called Apophysomyces and Saksenaea, which cause serious skin and soft tissue infections. These fungi are difficult to identify because they don’t form spores on standard laboratory media. The new test uses a simple method combining antibody detection with a rapid lateral-flow test, similar to a COVID-19 test, making diagnosis faster and more reliable in hospitals that don’t have access to expensive equipment.

Pathogenic mucorales: Deciphering their cell wall polysaccharidome and immunostimulatory potential

mycolabadmin

Researchers studied three dangerous fungi that cause serious infections called mucormycosis. They examined the outer coating of these fungi, called the cell wall, which is made of sugar-like molecules called polysaccharides. When these fungi were exposed to human immune cells, they triggered strong inflammatory responses. Understanding these fungal components could help develop better treatments and vaccines for this life-threatening infection.

Cutaneous Mucormycosis Following Polytrauma: A Multidisciplinary Approach

mycolabadmin

A 22-year-old man suffered severe injuries from a motorcycle-truck collision that damaged his perineal area and left thigh. Despite antibiotics and wound therapy, a dangerous fungal infection called mucormycosis developed in the wound. The medical team treated this by repeatedly removing infected tissue, using powerful antifungal medications (amphotericin B and posaconazole), and carefully managing the wound with special therapy before skin grafting, ultimately achieving successful healing.

The diagnosis of mucormycosis by PCR in patients at risk: a systematic review and meta-analysis

mycolabadmin

Mucormycosis is a dangerous fungal infection that kills many patients. Traditional tests like fungal culture are slow and often miss infections. This comprehensive study of 30 research papers shows that PCR testing is very effective at detecting this fungus, with different specimen types having different success rates. Blood tests were easiest to perform and worked well for screening high-risk patients, while fluid from the lungs was the most accurate.

Brazilian task force for the management of mucormycosis

mycolabadmin

Mucormycosis is a rare but deadly fungal infection that has been increasingly reported in Brazil, especially during the COVID-19 pandemic. This Brazilian medical task force developed practical guidelines for diagnosing and treating this serious infection, which primarily affects people with uncontrolled diabetes or weakened immune systems. The key to survival is early diagnosis combined with aggressive surgery and specific antifungal medications, along with controlling blood sugar and immune system suppression.

Disease: Cutaneous mucormycosis